Why did Piramal Pharma (PPLPHARMA) stock move recently?

On 7/27/2026, Piramal Pharma moved +5.9% — No specific positive catalyst identified; the stock rose amid broader market or sector sentiment following the July 24 disclosure of temporary Ahmedabad facility suspension due to flooding, which multiple reports described as having minimal revenue impact (under 3%) with insurance coverage and staff safety assured. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Piramal Pharma (PPLPHARMA) overvalued or fairly valued?

MarketChacha shows Piramal Pharma's valuation in context — a forward P/E of about 47.9, a price-to-book of about 3.2 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Piramal Pharma's revenue?

Piramal Pharma reported revenue of ₹4,782 Cr for FY2026, with net profit of ₹700 Cr, per official filings.

What is the share price of Piramal Pharma (PPLPHARMA)?

Piramal Pharma last traded at ₹194.44 (-1.7% on the day), as of 10/19/2026 — a delayed quote shown for education, not investment advice.

Piramal Pharma

PPLPHARMA · NSE · Pharma · India

Snapshot

TickerPPLPHARMA

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

Employees7,120

HeadquartersMumbai, India

Websitewww.piramalpharma.com

Filings tracked11

About Piramal Pharma

Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing; offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain management drugs, and other generic and speciality products; and analgesics, skin care, vitamin and mineral supplement, kids' wellness, digestives, and women's health, as well as geriatric care. In addition, the company operates as a contract development and manufacturing organization, providing process development, scale-up, and GMP manufacturing services for vaccines and biologics. The company was incorporated in 2020 and is based in Mumbai, India.

Who owns it

Promoters54.5%
Institutions19.9%
Public & other25.5%

65 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend-2.6% → -3.7%

Margin has held broadly steady over the period — stable profitability.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹2,478 Cr · EPS 0.21

Est. earnings growth +129.2%

Next fiscal year

Rev ₹11,731 Cr · EPS 4.06

Est. earnings growth +181.1%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 5

Revenue (FY2026)

₹8,869 Cr

Net margin

-3.7%

Revenue CAGR (3y)

+7.8%

Net profit (FY2026)

₹-326 Cr

Ask MarketChacha about PPLPHARMA

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jul 27, 2026
No specific positive catalyst identified; the stock rose amid broader market or sector sentiment following the July 24 disclosure of temporary Ahmedabad facility suspension due to flooding, which multiple reports described as having minimal revenue impact (under 3%) with insurance coverage and staff safety assured.
source 1 ↗source 2 ↗· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹8,869 Cr	₹-326 Cr	-3.7%
FY2025	₹9,151 Cr	₹91 Cr	1.0%
FY2024	₹8,171 Cr	₹18 Cr	0.2%
FY2023	₹7,082 Cr	₹-186 Cr	-2.6%

Quarterly

Period	Revenue	Net profit	Net margin
Q1 FY27	₹2,270 Cr	₹-69 Cr	-3.1%
Q4 FY26	₹2,752 Cr	₹-9 Cr	-0.3%
Q3 FY26	₹2,140 Cr	₹-136 Cr	-6.4%
Q2 FY26	₹2,044 Cr	₹-99 Cr	-4.9%
Q1 FY26	₹1,934 Cr	₹-82 Cr	-4.2%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

Filings & announcements

2026

Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 - ESG Rating -Niche Ninety Nine Capability And Certifications (OPC) Private Limited
Please refer attached file
BSE9/18/2026
Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 - FDA Inspection
Please refer attached file
BSE9/14/2026
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Deutsche Bank AG
BSE8/18/2026
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 -Resumption Of Operations At Company'S Facilities Located At Ahmedabad, Gujarat
Please refer attachment
BSE8/3/2026
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Report of the Scrutinizer along with the voting results of the businesses transacted at the AGM
BSE7/30/2026material
Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings and Voting Results of the 6th Annual General Meeting of the Company
BSE7/30/2026material
Investor Presentation
Please see enclosed Investor Presentation for Q1 FY 27
BSE7/29/2026
Press Release / Media Release
Please see enlcosed Press Release for Q1 FY 27
BSE7/29/2026
Unaudited Financial Results (Standalone & Consolidated) Of The Company For The Quarter Ended 30Th June, 2026
Please find enlcosed UFR Q1 FY 27.
BSE7/29/2026
Board Meeting Outcome for Outcome Of Board Meeting Of Piramal Pharma Limited Held On 29Th July, 2026
Please find enclosed outcome of Board Meeting of Piramal Pharma Limited held on 29th July, 2026
BSE7/29/2026
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Temporary Suspension Of Operations At Company'S Facilities Located At Ahmedabad, Gujarat.
Please refer attachment.
BSE7/24/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.